ideology-health
  • Our Solutions
  • About Us
  • Implementation strategies for amivantamab+chemotherapy in patients with mNSCLC that have progressed on osimertinib (MARIPOSA-2)
    Sign up to watch this video

    Free access to all Sound Bites content

    Implementation strategies for amivantamab+chemotherapy in patients with mNSCLC that have progressed on osimertinib (MARIPOSA-2)

    Published Jun 3, 2024


    D

    Dr. Martin Dietrich

    Medical Professional


    MARIPOSA-2 Implementation


    More in this series: MARIPOSA-2_2024
    Efficacy of Amivantamab + chemotherapy in patients with mNSCLC that have progressed on osimertinib (MARIPOSA-2)

    Efficacy of Amivantamab + chemotherapy in patients with mNSCLC that have progressed on osimertinib (MARIPOSA-2)

    MARIPOSA-2 Efficacy

    Dr. Martin Dietrich
    Lung Cancer
    Safety of amivantamab+chemotherapy in patients with mNSCLC that have progressed on osimertinib (MARIPOSA-2)

    Safety of amivantamab+chemotherapy in patients with mNSCLC that have progressed on osimertinib (MARIPOSA-2)

    MARIPOSA-2 Safety

    Dr. Martin Dietrich
    Lung Cancer
    Related Videos
    Dr. John Mascarenhas discusses how to recognize hydroxyurea resistance in essential thrombocythemia and when a treatment change may be appropriate (Video 1/3)

    Dr. John Mascarenhas discusses how to recognize hydroxyurea resistance in essential thrombocythemia and when a treatment change may be appropriate (Video 1/3)

    John Mascarenhas, MD
    Dr. Rahul Banerjee reviews the safety profile of iberdomide and strategies for adverse event management (Video 3/3)

    Dr. Rahul Banerjee reviews the safety profile of iberdomide and strategies for adverse event management (Video 3/3)

    Rahul Banerjee, MD
    Dr. Wade Iams describes an MDT approach to optimally care for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 3/3)

    Dr. Wade Iams describes an MDT approach to optimally care for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 3/3)

    Wade Iams, MD
    Dr. Rahul Banerjee highlights key findings with iberdomide, daratumumab, and dexamethasone in RRMM. (Video 2/3)

    Dr. Rahul Banerjee highlights key findings with iberdomide, daratumumab, and dexamethasone in RRMM. (Video 2/3)

    Rahul Banerjee, MD
    Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)

    Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)

    Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)

    Eytan Stein, MD
    ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.